1. Home
  2. SOTK vs ALXO Comparison

SOTK vs ALXO Comparison

Compare SOTK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sono-Tek Corporation

SOTK

Sono-Tek Corporation

HOLD

Current Price

$4.09

Market Cap

68.8M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$2.39

Market Cap

68.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOTK
ALXO
Founded
1975
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
68.3M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
SOTK
ALXO
Price
$4.09
$2.39
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
N/A
$3.42
AVG Volume (30 Days)
24.0K
893.3K
Earning Date
04-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.02
EPS
0.08
N/A
Revenue
$20,504,381.00
N/A
Revenue This Year
$4.02
N/A
Revenue Next Year
$10.95
N/A
P/E Ratio
$51.19
N/A
Revenue Growth
4.08
N/A
52 Week Low
$3.23
$0.41
52 Week High
$5.15
$2.66

Technical Indicators

Market Signals
Indicator
SOTK
ALXO
Relative Strength Index (RSI) 46.60 62.81
Support Level $4.05 $1.41
Resistance Level $4.18 N/A
Average True Range (ATR) 0.18 0.30
MACD -0.01 0.00
Stochastic Oscillator 44.04 65.38

Price Performance

Historical Comparison
SOTK
ALXO

About SOTK Sono-Tek Corporation

Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: